FIGURE 2.

LT recipients reaching the composite primary endpoint and developing chronic kidney disease, new-onset hypertension and new-onset diabetes after transplantation. A, Intention-to-treat and (B) PP show the proportion of LT recipients with 95% CI reaching the composite primary endpoint and developing the separate components of the composite primary endpoint in the intention-to-treat population and PP population: CKD defined as grade ≥3 (eGFR <60 mL/min/1.73 m²) for >3 mo during the follow-up, new-onset hypertension and PTDM. In the ITT population the composite primary endpoint at 12 mo was reached in 50.9% (27/53); 95% CI, 37.9%-63.9% of the LT recipients in the LCP-tacrolimus group vs 71.2% (37/52); 95% CI, 57.7%-81.7% of the LT recipients in the ER-tacrolimus group; risk difference: 0.202; 95% CI, 0.002-0.382; P = 0.046. In the PP population, the composite primary endpoint at 12 mo was reached in 41.4% (12/29); 95% CI, 25.5%-59.3% of the LT recipients in the LCP-tacrolimus group vs 64.3% (18/29), 95% CI, 45.8%-79.3% of the LT recipients in the ER-tacrolimus group; risk difference: 0.229; 95% CI, −0.051 to 0.467; P = 0.114. CI, confidence interval; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; ER, extended-release; LCP, life cycle pharma; LT, liver transplantation; ns, nonsignificant; PP, per protocol; PTDM, posttransplant diabetes.